Literature DB >> 24268210

The role of cardiovascular magnetic resonance imaging and computed tomography angiography in suspected non-ST-elevation myocardial infarction patients: design and rationale of the CARdiovascular Magnetic rEsoNance imaging and computed Tomography Angiography (CARMENTA) trial.

Martijn W Smulders1, Bastiaan L J H Kietselaer, Marco Das, Joachim E Wildberger, Harry J G M Crijns, Leo F Veenstra, Hans-Peter Brunner-La Rocca, Marja P van Dieijen-Visser, Alma M A Mingels, Pieter C Dagnelie, Mark J Post, Anton P M Gorgels, Antoinette D I van Asselt, Gaston Vogel, Simon Schalla, Raymond J Kim, Sebastiaan C A M Bekkers.   

Abstract

BACKGROUND: Although high-sensitivity cardiac troponin (hs-cTn) substantially improves the early detection of myocardial injury, it lacks specificity for acute myocardial infarction (MI). In suspected non-ST-elevation MI, invasive coronary angiography (ICA) remains necessary to distinguish between acute MI and noncoronary myocardial disease (eg, myocarditis), unnecessarily subjecting the latter to ICA and associated complications. This trial investigates whether implementing cardiovascular magnetic resonance (CMR) or computed tomography angiography (CTA) early in the diagnostic process may help to differentiate between coronary and noncoronary myocardial disease, thereby preventing unnecessary ICA. STUDY
DESIGN: In this prospective, single-center, randomized controlled clinical trial, 321 consecutive patients with acute chest pain, elevated hs-cTnT, and nondiagnostic electrocardiogram are randomized to 1 of 3 strategies: (1) CMR, or (2) CTA early in the diagnostic process, or (3) routine clinical management. In the 2 investigational arms of the study, results of CMR or CTA will guide further clinical management. It is expected that noncoronary myocardial disease is detected more frequently after early noninvasive imaging as compared with routine clinical management, and unnecessary ICA will be prevented. The primary end point is the total number of patients undergoing ICA during initial admission. Secondary end points are 30-day and 1-year clinical outcome (major adverse cardiac events and major procedure-related complications), time to final diagnosis, quality of life, and cost-effectiveness.
CONCLUSION: The CARMENTA trial investigates whether implementing CTA or CMR early in the diagnostic process in suspected non-ST-elevation MI based on elevated hs-cTnT can prevent unnecessary ICA as compared with routine clinical management, with no detrimental effect on clinical outcome.
© 2013.

Entities:  

Mesh:

Year:  2013        PMID: 24268210     DOI: 10.1016/j.ahj.2013.09.012

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Acute myocardial infarction or acute myocarditis? Discharge registry-based study of likelihood and associated features in hospitalised patients.

Authors:  Ville Kytö; Jussi Sipilä; Päivi Rautava
Journal:  BMJ Open       Date:  2015-05-25       Impact factor: 2.692

Review 2.  Cardiac magnetic resonance and computed tomography angiography for clinical imaging of stable coronary artery disease. Diagnostic classification and risk stratification.

Authors:  Grigorios Korosoglou; Sorin Giusca; Gitsios Gitsioudis; Christian Erbel; Hugo A Katus
Journal:  Front Physiol       Date:  2014-08-06       Impact factor: 4.566

3.  Cardiovascular magnetic resonance accurately detects obstructive coronary artery disease in suspected non-ST elevation myocardial infarction: a sub-analysis of the CARMENTA Trial.

Authors:  Yvonne J M van Cauteren; Martijn W Smulders; Ralph A L J Theunissen; Suzanne C Gerretsen; Bouke P Adriaans; Geertruida P Bijvoet; Alma M A Mingels; Sander M J van Kuijk; Simon Schalla; Harry J G M Crijns; Raymond J Kim; Joachim E Wildberger; Jordi Heijman; Sebastiaan C A M Bekkers
Journal:  J Cardiovasc Magn Reson       Date:  2021-03-22       Impact factor: 5.364

4.  Biotin interference in high-sensitivity cardiac troponin T testing: a real-world evaluation in acute cardiac care.

Authors:  Wim H M Vroemen; William P T M van Doorn; Dorien M Kimenai; Will K W H Wodzig; Douwe de Boer; Otto Bekers; Steven J R Meex
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 13.081

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.